Haleon (NYSE: HLN) updates total voting rights with 8.91B shares

Rhea-AI Filing Summary

Haleon plc reported its share capital and voting rights as of 30 November 2025. The company has issued a total of 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares. This leaves 8,906,471,490 ordinary shares with voting rights.

The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	01 December 2025 - “Total Voting Rights and Capital”

99.1

Haleon plc: Total Voting Rights and Capital

01 December 2025: As at 30 November 2025 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,906,471,490 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: December 01, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many Haleon (HLN) shares were issued as of 30 November 2025?

As of 30 November 2025, Haleon plc had 8,952,353,648 ordinary shares of £0.01 each issued.

How many Haleon (HLN) shares carry voting rights as of 30 November 2025?

As of 30 November 2025, Haleon had 8,906,471,490 ordinary shares with voting rights, after excluding treasury shares.

How many Haleon (HLN) shares are held in treasury?

Haleon plc held 45,882,158 of its ordinary shares as treasury shares as of 30 November 2025.

What denominator should Haleon (HLN) investors use for FCA disclosure calculations?

Investors should use 8,906,471,490 ordinary shares with voting rights as the denominator for FCA Disclosure Guidance and Transparency Rules calculations.

Who is the company secretary of Haleon plc mentioned in this report?

The company secretary of Haleon plc named in the report is Amanda Mellor.

In which sectors does Haleon (HLN) operate as a consumer health company?

Haleon operates across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other.